Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.39
BGMD's Cash to Debt is ranked higher than
64% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BGMD: 1.39 )
BGMD' s 10-Year Cash to Debt Range
Min: 0.23   Max: No Debt
Current: 1.39

Equity to Asset 0.11
BGMD's Equity to Asset is ranked lower than
52% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. BGMD: 0.11 )
BGMD' s 10-Year Equity to Asset Range
Min: -11.02   Max: 0.8
Current: 0.11

-11.02
0.8
F-Score: 3
Z-Score: -43.66
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -264.16
BGMD's Operating margin (%) is ranked higher than
52% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. BGMD: -264.16 )
BGMD' s 10-Year Operating margin (%) Range
Min: -1783.39   Max: -69.34
Current: -264.16

-1783.39
-69.34
Net-margin (%) -289.38
BGMD's Net-margin (%) is ranked higher than
52% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. BGMD: -289.38 )
BGMD' s 10-Year Net-margin (%) Range
Min: -2095.48   Max: -78.43
Current: -289.38

-2095.48
-78.43
ROE (%) -1924.82
BGMD's ROE (%) is ranked lower than
58% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. BGMD: -1924.82 )
BGMD' s 10-Year ROE (%) Range
Min: -224.23   Max: -224.23
Current: -1924.82

ROA (%) -101.92
BGMD's ROA (%) is ranked lower than
52% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. BGMD: -101.92 )
BGMD' s 10-Year ROA (%) Range
Min: -174.66   Max: -67.46
Current: -101.92

-174.66
-67.46
ROC (Joel Greenblatt) (%) -4774.32
BGMD's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. BGMD: -4774.32 )
BGMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9127.71   Max: -327.37
Current: -4774.32

-9127.71
-327.37
EBITDA Growth (3Y)(%) -39.00
BGMD's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. BGMD: -39.00 )
BGMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -39
Current: -39

EPS Growth (3Y)(%) -37.00
BGMD's EPS Growth (3Y)(%) is ranked higher than
58% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. BGMD: -37.00 )
BGMD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -37
Current: -37

» BGMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BGMD Guru Trades in Q1 2014

Paul Tudor Jones 11,879 sh (-57.03%)
» More
Q2 2014

BGMD Guru Trades in Q2 2014

Paul Tudor Jones 11,879 sh (unchged)
» More
Q3 2014

BGMD Guru Trades in Q3 2014

Paul Tudor Jones 11,779 sh (-0.84%)
» More
Q4 2014

BGMD Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BGMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 37.50
BGMD's P/B is ranked lower than
65% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. BGMD: 37.50 )
BGMD' s 10-Year P/B Range
Min: 2.56   Max: 141.5
Current: 37.5

2.56
141.5
P/S 8.84
BGMD's P/S is ranked lower than
57% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. BGMD: 8.84 )
BGMD' s 10-Year P/S Range
Min: 3.33   Max: 121
Current: 8.84

3.33
121
Current Ratio 1.06
BGMD's Current Ratio is ranked higher than
50% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. BGMD: 1.06 )
BGMD' s 10-Year Current Ratio Range
Min: 0.2   Max: 4.87
Current: 1.06

0.2
4.87
Quick Ratio 0.97
BGMD's Quick Ratio is ranked higher than
52% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BGMD: 0.97 )
BGMD' s 10-Year Quick Ratio Range
Min: 0.2   Max: 4.82
Current: 0.97

0.2
4.82
Days Inventory 163.89
BGMD's Days Inventory is ranked higher than
66% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. BGMD: 163.89 )
BGMD' s 10-Year Days Inventory Range
Min: 62.5   Max: 163.98
Current: 163.89

62.5
163.98
Days Sales Outstanding 22.79
BGMD's Days Sales Outstanding is ranked higher than
97% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. BGMD: 22.79 )
BGMD' s 10-Year Days Sales Outstanding Range
Min: 11.95   Max: 350.29
Current: 22.79

11.95
350.29

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 75.00
BGMD's Price/Tangible Book is ranked lower than
57% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. BGMD: 75.00 )
BGMD' s 10-Year Price/Tangible Book Range
Min: 2.84   Max: 92
Current: 75

2.84
92
Price/Median PS Value 0.70
BGMD's Price/Median PS Value is ranked higher than
94% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BGMD: 0.70 )
BGMD' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 3.58
Current: 0.7

0.43
3.58
Earnings Yield (Greenblatt) -29.70
BGMD's Earnings Yield (Greenblatt) is ranked lower than
60% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BGMD: -29.70 )
BGMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.2   Max: 0
Current: -29.7

-36.2
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:RBM.Germany,
BG Medicine is a life sciences company engaged into discovery, development, and commercialization of novel diagnostic tests based on biomarkers. Its tests include BGM Galectin-3, CardioSCORE.
» More Articles for BGMD

Headlines

Articles On GuruFocus.com
comment on BGMD Jun 09 2011 

More From Other Websites
10-K for BG Medicine, Inc. Apr 25 2015
Nasdaq stocks posting largest volume increases Apr 24 2015
Most active Nasdaq-traded stocks Apr 24 2015
BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 15 2015
BG MEDICINE, INC. Financials Apr 07 2015
BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test Mar 31 2015
BG Medicine Reports 2014 Fourth Quarter and Year End Financial Results Mar 31 2015
BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test Mar 31 2015
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Mar 31 2015
Q4 2014 BG Medicine Inc Earnings Release - Before Market Open Mar 31 2015
BG Medicine Reports 2014 Fourth Quarter and Year End Financial Results Mar 31 2015
BG Medicine Welcomes Major Publication on the BioImage Study in the Journal of the American College... Mar 26 2015
BG Medicine Welcomes Major Publication on the BioImage Study in the Journal of the American College... Mar 26 2015
BG Medicine Announces Fiscal Year 2014 Financial Results Release Date and Conference Call... Mar 24 2015
BG Medicine Announces Fiscal Year 2014 Financial Results Release Date and Conference Call... Mar 24 2015
BG Medicine Announces Receipt of NASDAQ Notice of Non-Compliance; Intends to Request Hearing and... Mar 13 2015
BG Medicine Announces Receipt of NASDAQ Notice of Non-Compliance; Intends to Request Hearing and... Mar 13 2015
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Mar 13 2015
BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination Feb 02 2015
BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination Feb 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK